S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx

• Status: Terminated
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known whether giving combination chemotherapy together with radiation therapy is more effective than giving cisplatin together with radiation therapy in treating cancer of the oropharynx.

PURPOSE: This randomized phase III trial is studying combination chemotherapy and radiation therapy to see how well they work compared to cisplatin and radiation therapy in treating patients with stage III or stage IV cancer of the oropharynx.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cisplatin; Docetaxel; Fluorouracil

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed squamous cell carcinoma of the oropharynx by biopsy or fine needle aspiration of the primary lesion or neck mass

• Selected stage III or IV disease

• No T1-2, N1 disease

• No T4b disease

• No other primary tumor sites or unknown primary tumor sites

• Previously untreated disease

• Measurable or non-measurable disease by clinical exam, CT scan or MRI

• Disease considered to be curatively resectable

• Patients for whom surgical excision is unlikely to result in clear margins are not eligible, including patients with any of the following:

• Gross extension of tumor to skull base (e.g., T4b disease)

• Severe trismus

• Pterygoid plate erosion

• Sphenoid bone or foramen ovale involvement

• Direct extension to involve prevertebral-fascia

• Extension to superior nasopharynx or eustachian tube

• Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)

• Suspected invasion (encasement) of the common or internal carotid arteries (T4b)

• Direct extension of neck disease to involve the external skin

• Regional metastases to the supraclavicular neck (IVB low level VB nodes)

• Disease must be appropriate for definitive radiotherapy with curative intent

• No evidence of distant metastases (M1)

• Must have negative chest x-ray

PATIENT CHARACTERISTICS:

• Zubrod performance status 0-1

• No myocardial infarction within the past 3 months

• No unstable or uncontrolled angina

• No active systemic infection

• Granulocyte count > 1,500/mm^3

• Platelet count > 100,000/mm^3

• Creatinine < 1.5 mg/dL

• Bilirubin normal

• Alkaline phosphatase ≤ 2 times upper limit of normal (ULN)

• SGOT or SGPT ≤ 1.5 times ULN

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No history of hypersensitivity reaction to products containing polysorbate 80

• No medical contraindication to surgery as defined by the treating institution

• No clinically significant motor or sensory neuropathy ≥ grade 2

• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer from which the patient is in complete remission

PRIOR CONCURRENT THERAPY:

• No prior therapeutic surgery for head and neck cancer

• No prior radiotherapy

• No prior chemotherapy